Patient-Level VHA Data Show No Association Between Paclitaxel-Coated Devices and Long-Term Mortality Created with Sketch. February 23, 2021—In the first study examining the impact of paclitaxel-coated device (PCD) use on mortality in patients treated within the Veterans Health Administration (VHA), Gutierrez et al found no increased risk of long-term all-cause mortality associated with PCD use. The study was recently published in the KEY FINDINGS The rates of 2- and 3-year all-cause mortality were similar between the PCD and non-PCD groups, even when stratified by claudication or critical limb ischemia presentations. No statistically significant risk in all-cause mortality was seen between the use of PCD and non-PCD devices after adjustment for treatment assignment.